SLC7A5 and metastatic malignant neoplasm: As of now, QBS10072S is under investigation in a Phase I clinical trial involving previously treated patients with advanced or metastatic cancers characterized by high LAT1 expression, as well as those with relapsed or refractory GBM (ClinicalTrials.gov Identifier: NCT04430842).